BIOADAPTIVES, INC.
For the period ended Dec 31, 2025. Filed Apr 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 14, 2026
BDPTStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheet
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current Assets: | ||
| Cash | $158,445 | $137,470 |
| Inventory | 44,706 | 19,115 |
| Security deposit | 2,500 | 2,500 |
| Prepaid expense | 6,250 | 100,000 |
| Other receivable | - | 2,800 |
| Total Current Assets | 211,901 | 261,885 |
| Property and equipment, net | 14,000 | - |
| TOTAL ASSETS | $225,901 | $261,885 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
| Current Liabilities: | ||
| Accounts payable and accrued liabilities | 232,725 | 179,458 |
| Derivative liabilities | 1,738,804 | 1,053,249 |
| Convertible notes | 352,332 | 461,000 |
| Notes Payable | 32,096 | 32,096 |
| Total Current Liabilities | 2,355,957 | 1,725,803 |
| Total Liabilities | 2,355,957 | 1,725,803 |
| Stockholders' Deficit: | ||
| Preferred stock, ($.0001 par value, 31,000,000 shares authorized; | ||
| Series A Preferred Stock 4,000,000 shares designated; 11,167 issued and outstanding as of December 31, 2025 and 2024 | 1 | 1 |
| Series B Preferred Stock 5,000,000 shares designated; 9,667 share issued and outstanding as of December 31, 2025 and 2024 | 1 | 1 |
| Series C Preferred Stock 1,000,000 shares designated; 1,000,000 share issued and outstanding as of December 31, 2025 and 2024 | 100 | 100 |
| Series D Preferred Stock 20,000,000 shares designated; 198,335 and 72,687 share issued and outstanding as of December 31, 2025 and 2024, respectively | 20 | 7 |
| Common stock ($.0001 par value, 1,250,000,000 shares authorized; 12,008,725 and 8,215,426 shares issued and outstanding as of December 31, 2025 and 2024, and 66 issuable, respectively) | 1,200 | 821 |
| Additional paid-in capital | 8,595,711 | 7,704,343 |
| Subscription receivable | (5,885) | (5,885) |
| Accumulated deficit | (10,721,204) | (9,163,306) |
| Total Stockholders' Deficit | (2,130,056) | (1,463,918) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $225,901 | $261,885 |
F- 3
Table of Contents
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.